

# A multicentre phase III randomised controlled study of Theratope vaccine for metastatic breast cancer

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/03/2015	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

--

### Contact details

UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

### Protocol serial number

C136

## Study information

### Scientific Title

A multicentre phase III randomised controlled study of Theratope vaccine for metastatic breast cancer

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Breast cancer

**Interventions**

1. Theratope s/c injections 100 mg with detox at weeks 0, 2, 5 and 9
2. Control injection Keyhole limpet haemocyanin 100 mg with detox at weeks 0, 2, 5 and 9

**Intervention Type**

Drug

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Theratope

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/2005

**Eligibility****Key inclusion criteria**

1. Must have received 4-8 cycles or 12-24 weeks duration of first-line chemotherapy for metastatic disease
2. Has either no evidence of disease or non-progressive disease following first-line chemotherapy or stable disease

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Female

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2000

**Date of final enrolment**

31/12/2005

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

UK Co-ordinating Committee for Cancer Research (UKCCCR)

**ROR**

<https://ror.org/054225q67>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Cancer organisations

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration